STIFEL 2026: Korsana Biosciences is using a proprietary brain shuttle and a beta amyloid targeting therapy and aims to take Alzheimer's treatment to the next level
STIFEL 2026: Korsana Biosciences is using a proprietary brain shuttle and a beta amyloid targeting therapy and aims to take Alzheimer's treatment to the next level
President and CEO Jonathan Violin compares and contrasts his product with other brain shuttles and discusses the road ahead. They will present preclinical data at CTAD next week and the clinical program will ramp up and have initial data in 2027. Korsana recently went public through a reverse merger.
AI 伴隨問答
針對這篇報導有疑問?可直接點選快捷問題或向 AI 追問背景脈絡與技術細節:
Podcast 專家音訊節目
收錄於 888news Podcast 智庫專區,包含精華摘要與上市公司即時行情
President and CEO Jonathan Violin compares and contrasts his product with other brain shuttles and discusses the road ahead. They will present preclinical data at CTAD next week and the clinical program will ramp up and have initial data in 2027. Korsana recently went public through a reverse merger.